In the rapidly evolving field of biochemical research, the study of protein-protein interactions has opened new doors for understanding cellular signaling. My journey into this niche began with a fascination for the Hippo pathway and its regulatory components. Among the various compounds I have encountered, Peptide 17 stands out as a significant subject of study, particularly regarding its role as a YAP-TEAD protein-protein interaction inhibitor.
Understanding the Mechanism of Peptide 17
When analyzing Peptide 17, it is essential to recognize its structural classification. It is a 17mer peptide designed to modulate the Hippo signaling pathway. In my review of the existing literature, I found it fascinating that Peptide 17 exhibits a binding affinity The Hippo pathway is an important organ size control signaling network and the major regulatory mechanism of cell-contact inhibition. to TEAD1 (Kd = 15 nM) that is notably stronger than that of the native YAP (50-171) fragment (Kd = 40 nM). This high affinity makes it a precise tool for researchers looking to investigate the complex dynamics of YAP-TEAD-IN-1, which is a 17mer peptide frequently utilized in laboratory settings.
From my personal perspective, the specificity of these inhibitors is what makes them so valuable. Whether one is looking at YAP-TEAD Inhibitor 1 (Peptide 17) for cellular assays or exploring its biochemical properties, the precision afforded by an IC50 of 25 nM allows for highly controlled experimental environments.
Research Context and Applications
The discourse surrounding Peptide 17 often touches upon its potential in various research models. One of the most compelling areas of study involves how Peptide 17 alleviates early renal injury in hypertension. By regulating the Hippo/YAP signaling pathway, this compound provides a unique lens through which scientists can observe cellular responses to stress.
Furthermore, YAP and TAZ are TEAD coacti Targeting Hippo pathway by specific interruption of YAP vators (1, 17, 18) that play a pivotal role in maintaining cellular homeostasis. Because YAP1/TAZ signaling is crucial for cancer and wound healing, many researchers focus on how a YAP peptide can interfere with these pathways to inhibit unwanted proliferation. It is important to note that Peptide 17 is a inhibitor of this YAP-TEAD protein-protein interaction, and while some newer variants like YTP-17 is an orally active YAP-TEAD protein-protein interaction inhibitor are emerging, the original Peptide 17 remains a foundational reference point in molecular biology labs.
Observations on Quality and Efficacy
When sourcing high-purity reagents like Peptide 17, consistency is key. My experience indicates that the YAP-TEAD-IN-1 TFA is a 17mer peptide that requires careful h by AD Guarnaccia·2025·Cited by 7—YAP and TAZ are TEAD coactivators (1, 17, 18) and can be oncogenic, as they are frequently observed to have high nuclear levels and activity in cancers (4 Read more andling to maintain its structural integrity. In my observations, the potency of the inhibitor is directly linked to the purity of the synthetic product. Researchers often compare this to other emerging molecules, such as those discussed in the broader context of best peptide for kidney repair or peptides for kidney repair, though Peptide 17 remains distinct due to its specific target.
Final Thoughts
The study of the Hippo pathway remains one of the most intellectually stimulating areas of modern research. Whether you are investigating the nuances of Yap signaling or comparing different inhibitors, the data surrounding peptide 17 provides a robust framework for scientific inquiry. It is a testament to the power of structure-based design that a specific 17mer peptide can serve as such a potent interruptor of complex protein associations.
For those engaging i YAP-TEAD Inhibitor 1 (Peptide 17)は、YAP-TEADタンパク質間相互作用阻害剤であり、IC50 25 nMでYAPが関与する癌の治療に用いられる可能性があります。Read more n this field, staying updated on the latest citati Peptide 17, an inhibitor of YAP/TEAD4 pathway, mitigates ons regarding YAP-TEAD Inhibitor 1 (Peptide 17) is vital. As we continue to refine our understanding of these signaling cascades, the role of specialized inhibitors will un by X Li·2022·Cited by 80—We find that inhibition of Hippo/MST1/2 or activation ofYAPblocks the ERα transcriptional program and ER + breast cancer growth.Read more doubtedly become even more significant in uncovering the mysteries of sig YAP-TEAD Inhibitor 1 (Peptide 17) is a YAP-TEAD protein-protein interaction inhibitor which has potential usage in treatment of YAP-involved cancers with IC50 Read more nal transduction.